FDA Grants Orphan Drug Designation to Azeliragon for Glioblastoma
Cancer Network,
Azeliragon was first evaluated in a group of patients with Alzheimer’s disease prior to being assessed in patients with…
Azeliragon was first evaluated in a group of patients with Alzheimer’s disease prior to being assessed in patients with…
The FDA has granted an orphan drug designation to azeliragon (formerly TTP488) for the treatment of patients with glioblastoma (G…